Equities analysts predict that Dare Bioscience Inc (NASDAQ:DARE) will post ($0.18) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Dare Bioscience’s earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Dare Bioscience posted earnings per share of ($0.23) in the same quarter last year, which suggests a positive year over year growth rate of 21.7%. The company is scheduled to issue its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Dare Bioscience will report full-year earnings of ($0.88) per share for the current fiscal year, with EPS estimates ranging from ($0.96) to ($0.84). For the next year, analysts expect that the company will post earnings of ($0.72) per share, with EPS estimates ranging from ($0.83) to ($0.50). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Dare Bioscience.
Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09).
Shares of DARE traded up $0.01 on Monday, reaching $0.87. The stock had a trading volume of 37,953 shares, compared to its average volume of 83,647. The firm has a market capitalization of $14.51 million, a PE ratio of -0.80 and a beta of 1.89. The firm has a 50-day moving average of $0.79 and a 200 day moving average of $0.95. Dare Bioscience has a twelve month low of $0.60 and a twelve month high of $3.25.
An institutional investor recently raised its position in Dare Bioscience stock. Susquehanna International Group LLP raised its stake in shares of Dare Bioscience Inc (NASDAQ:DARE) by 293.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 42,770 shares of the biotechnology company’s stock after buying an additional 31,900 shares during the quarter. Susquehanna International Group LLP owned about 0.26% of Dare Bioscience worth $36,000 at the end of the most recent reporting period. 5.11% of the stock is currently owned by institutional investors.
Dare Bioscience Company Profile
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
See Also: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.